Literature DB >> 22387049

The disturbed blood-brain barrier in human glioblastoma.

Hartwig Wolburg1, Susan Noell, Petra Fallier-Becker, Andreas F Mack, Karen Wolburg-Buchholz.   

Abstract

The aim of this article is to describe alterations of the blood-brain barrier (BBB) in gliomas. The main clinical problem of human gliomas is the edematous swelling and the dramatic increase of intracerebral pressure, also compromising healthy areas of the brain. According to our concept, one of the main reasons on the cellular level for these clinical problems is the loss or reduction of astroglial polarity. Astroglial polarity means the specific accumulation of potassium and water channels in the superficial and perivascular astroglial endfeet membranes. The most important water channel in the CNS is the astroglial water channel protein aquaporin-4 (AQP4) which is arranged in a morphologically spectacular way, the so-called orthogonal arrays of particles (OAPs) to be observed in freeze-fracture replicas. In brain tumors, but also under conditions of trauma or inflammation, these OAPs are redistributed to membrane domains apart from endfeet areas. Probably, this dislocation might be due to the degradation of the proteoglycan agrin by the matrix metalloproteinase 3 (MMP3). Agrin binds to the dystrophin-dystroglycan-complex (DDC), which in turn is connected to AQP4. As a consequence, agrin loss may lead to a redistribution of AQP4 and a compromised directionality of water transport out of the cell, finally to cytotoxic edema. This in turn is hypothesized to lead to a breakdown of the BBB characterized by disturbed tight junctions, and thus to the development of vasogenic edema. However, the mechanism how the loss of polarity is related to the disturbance of microvascular tight junctions is completely unknown so far.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387049     DOI: 10.1016/j.mam.2012.02.003

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  96 in total

Review 1.  Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.

Authors:  Linfeng Wu; Xiaoxun Li; Dileep R Janagam; Tao L Lowe
Journal:  Pharm Res       Date:  2013-08-31       Impact factor: 4.200

2.  Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3-Targeted Liposomes.

Authors:  Anirudh Sattiraju; Xiaobing Xiong; Darpan N Pandya; Thaddeus J Wadas; Ang Xuan; Yao Sun; Youngkyoo Jung; Kiran Kumar Solingapuram Sai; Jay F Dorsey; King C Li; Akiva Mintz
Journal:  Mol Cancer Ther       Date:  2017-06-15       Impact factor: 6.261

3.  Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma.

Authors:  Zachary Miklja; Viveka Nand Yadav; Rodrigo T Cartaxo; Ruby Siada; Chase C Thomas; Jessica R Cummings; Brendan Mullan; Stefanie Stallard; Alyssa Paul; Amy K Bruzek; Kyle Wierzbicki; Tao Yang; Taylor Garcia; Ian Wolfe; Marcia Leonard; Patricia L Robertson; Hugh Jl Garton; Daniel R Wahl; Hemant Parmar; Jann N Sarkaria; Cassie Kline; Sabine Mueller; Theodore Nicolaides; Chana Glasser; Sarah Es Leary; Sriram Venneti; Chandan Kumar-Sinha; Arul M Chinnaiyan; Rajen Mody; Manjunath P Pai; Timothy N Phoenix; Bernard L Marini; Carl Koschmann
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

4.  In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models.

Authors:  Cindy Leten; Tom Struys; Tom Dresselaers; Uwe Himmelreich
Journal:  J Neurooncol       Date:  2014-07-03       Impact factor: 4.130

5.  Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.

Authors:  Jamey P Weichert; Paul A Clark; Irawati K Kandela; Abram M Vaccaro; William Clarke; Marc A Longino; Anatoly N Pinchuk; Mohammed Farhoud; Kyle I Swanson; John M Floberg; Joseph Grudzinski; Benjamin Titz; Anne M Traynor; Hong-En Chen; Lance T Hall; Christopher J Pazoles; Perry J Pickhardt; John S Kuo
Journal:  Sci Transl Med       Date:  2014-06-11       Impact factor: 17.956

6.  The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.

Authors:  W Hans Meisen; Eric S Wohleb; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Ji Young Yoo; Luke Russell; Jayson Hardcastle; Samuel Dubin; Kamaldeen Muili; Jianhua Yu; Michael Caligiuri; Jonathan Godbout; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

Review 7.  Advances in immunotherapeutic research for glioma therapy.

Authors:  Jeremy Tetsuo Miyauchi; Stella E Tsirka
Journal:  J Neurol       Date:  2017-12-05       Impact factor: 4.849

8.  Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.

Authors:  Janice K Laramy; Minjee Kim; Shiv K Gupta; Karen E Parrish; Shuangling Zhang; Katrina K Bakken; Brett L Carlson; Ann C Mladek; Daniel J Ma; Jann N Sarkaria; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2017-08-28       Impact factor: 4.030

9.  Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.

Authors:  Tanner M Johanns; Jay A Bowman-Kirigin; Connor Liu; Gavin P Dunn
Journal:  Neurosurgery       Date:  2017-09-01       Impact factor: 4.654

10.  PI3K/AKT/Afadin signaling pathway contributes to pathological vascularization in glioblastomas.

Authors:  Xuan Zhai; Yingliang Li; Ping Liang; Lusheng Li; Yudong Zhou; Weidan Zhang; Difei Wang; Guanghui Wei
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.